Regional Bioequivalence Centre for CARICOM, Barbados

Place your generic development work in Barbados: stability testing, bioequivalence and reformulation. IP income is taxed at 4.5 per cent, and development spend carries a 50 per cent R&D credit and a 25 per cent productivity and innovation credit.

Barbados sits in ICH Zone IVb. That matters...

BPI was established by the Government of Barbados to build pharmaceutical manufacturing capability and position the country as a production and distribution point for CARICOM and the Global South.

BPI holds the national pharmaceutical sector strategy. For a manufacturer or investor weigh...

One visit, everyone who decides. Register your interest in the 2027 inbound mission.

Barbados is hosting an inbound trade mission in 2027 for companies considering manufacturing, supply or partnership in the Caribbean. One visit puts you in front of the people who decide: the Ministry of Health, the Barbados Medical Products Authority and time on site at Newton Life Science Park and the AMA joint venture. In a country this size that is one week rather than a year of scheduling. Places are limited. Register your interest and you get the dates and the programme before they are announced.

Barbados Pharmaceutical Inc. is the commercial arm of the Government of Barbados, set up to build pharmaceutical manufacturing for a Caribbean and Latin American market of around 660 million people that imports almost everything it dispenses. CARICOM alone buys USD 2.8 billion of medicines a year, most of it through public tenders. BPI structures the investment and partnerships behind that shift, so a company deals with one counterparty for policy, incentives, regulatory pathway and commercial terms. A medicines regulatory authority is established in law, the incentives include a refundable 50 percent R&D credit and duty free inputs, and five projects are in active development. Our Investment Promotion Office in Charleroi, Belgium is the route in for European and global companies.